CLAYTON – Global life science firm Novo Nordisk will invest another $22 million and add 22 additional jobs at its growing manufacturing facility in Johnston County.

The company announced the additional investment and jobs on Monday.

It’s the fourth expansion in Johnston County since 2010 and follows a $65 million commitment to grow the facility in late 2017.

The facility is used for Diabetes Finished Products manufacturing. Nearly 1,200 people already work there.

Johnston County will provide local tax incentives spread across seven years.

Novo Nordisk strengthens diabetes treatment arsenal with $800M deal

“We greatly appreciate the support of the Johnston County Board of Commissioners and the community at large for the quarter century we’ve called Clayton home,” said Chad Henry, corporate vice president and general manager of Novo Nordisk’s Diabetes Finished Products manufacturing site, in a statement.

The Novo Nordisk plant opened in 1993.

The firm, which is based in Denmark, also is building a $2 billion plant for Diabetes Active Pharmaceutical Ingredients (DAPI) that will employ some 700 people.

“Johnston County leaders are proud to reiterate our support for Novo Nordisk and celebrate the mutually-beneficial partnership we have with this growing corporate resident,” said Ted Godwin, chairman of the Johnston County Board of Commissioners. “This global biopharma company has made our county a visible part of its production strategy, and I think that says all the right things about our business climate.”

Novo Nordisk tops off $2B expansion in Clayton

Novo Nordisk plans $65M expansion of Clayton manufacturing site